SZLSF (StageZero Life Sciences) EV-to-Revenue : 1.36 (As of Dec. 12, 2024)

View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, StageZero Life Sciences's enterprise value is $2.26 Mil. StageZero Life Sciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $1.66 Mil. Therefore, StageZero Life Sciences's EV-to-Revenue for today is 1.36.

The historical rank and industry rank for StageZero Life Sciences's EV-to-Revenue or its related term are showing as below:

SZLSF' s EV-to-Revenue Range Over the Past 10 Years
Min: -96.3 Med: 8.43 Max: 225.67
Current: 1.36

During the past 13 years, the highest EV-to-Revenue of StageZero Life Sciences was 225.67. The lowest was -96.30. And the median was 8.43.

SZLSF's EV-to-Revenue is ranked better than
50.93% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.06 vs SZLSF: 1.36

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-12), StageZero Life Sciences's stock price is $0.0016. StageZero Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.01. Therefore, StageZero Life Sciences's PS Ratio for today is 0.12.

StageZero Life Sciences EV-to-Revenue Historical Data

The historical data trend for StageZero Life Sciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences EV-to-Revenue Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-Revenue

Get a 7-Day Free Trial

42.45

84.06

7.83

4.05

1.70

StageZero Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24
EV-to-Revenue	Get a 7-Day Free Trial															2.84	2.25	2.11	3.09	3.45

Competitive Comparison of StageZero Life Sciences's EV-to-Revenue

For the Diagnostics & Research subindustry, StageZero Life Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StageZero Life Sciences's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's EV-to-Revenue falls into.

StageZero Life Sciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

StageZero Life Sciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2.256	/	1.657
	=	1.36

StageZero Life Sciences's current Enterprise Value is $2.26 Mil.
StageZero Life Sciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.66 Mil.

StageZero Life Sciences (OTCPK:SZLSF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

StageZero Life Sciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.0016	/	0.013
	=	0.12

StageZero Life Sciences's share price for today is $0.0016.
StageZero Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

StageZero Life Sciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.